Panacea Biotec Limited , a prominent player in the pharmaceutical industry, has recently received approval from both the Bombay Stock Exchange (BSE) and the National Stock Exchange of India (NSE) for a significant change in its shareholder classification. The company announced on July 29, 2025, that it has successfully reclassified three members of the Jain family from the "Promoters and Promoters' Group" category to the "Public" category of shareholders.

Reclassification Details

The reclassification applies to the following individuals:

1. Mrs. Sunanda Jain
2. Mr. Sumit Jain
3. Ms. Radhika Jain

This move comes after Panacea Biotec submitted an application for reclassification on October 16, 2024. The approval from both stock exchanges marks a significant milestone in the company's corporate structure.

Impact on Shareholding

Despite this reclassification, it's important to note that there will be no change in the aggregate shareholding of the Promoters and Promoters' Group. This is because none of the outgoing members hold any shares in the company. The shareholding structure remains as follows:

This structure remains identical both pre and post-reclassification, emphasizing that the change is primarily administrative in nature.

Regulatory Compliance

The reclassification has been carried out in accordance with Regulation 31A of the Securities and Exchange Board of India (SEBI) Listing Obligations and Disclosure Requirements Regulations, 2015. Panacea Biotec has duly informed the stock exchanges of this material event, as required by regulatory guidelines.

Company Statement

Vinod Goel, Group CFO and Head Legal & Company Secretary of Panacea Biotec, confirmed the development in a statement to the stock exchanges. He emphasized that the reclassification was approved in line with the provisions of Regulation 31A(3) of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

This reclassification represents a significant corporate action for Panacea Biotec, potentially impacting the company's governance structure and public perception. However, with no change in actual shareholding patterns, the immediate financial implications for the company and its operations are likely to be minimal.

Investors and market watchers will be keen to observe any long-term effects this reclassification might have on the company's strategic decisions and market positioning in the coming months.

Panacea Biotec , a prominent player in the pharmaceutical industry, has encountered a new financial challenge as it receives a fresh Goods and Services Tax (GST) demand of 70.3 million rupees. This development comes as part of an ongoing tax-related matter for the company.

Background of the GST Demand

The latest GST demand is part of a larger tax issue that Panacea Biotec has been dealing with. According to the company's disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this new demand is connected to a previous tax matter involving the transfer of leasehold rights in Navi Mumbai.

Details of the New Demand

As per the LODR data, the Assistant Commissioner of State Tax, GST Bhawan, Mazgaon, Mumbai, Maharashtra, has issued a Demand Order dated July 10, 2025, under Section 73(9) of the Central Goods & Service Tax Act, 2017 / Maharashtra Goods & Service Tax Act, 2017. The order raises a total demand of ₹70,343,082, which includes:

• Principal GST amount: ₹38,777,112
• Interest: ₹25,085,970
• Penalty: ₹6,480,000

It's worth noting that this amount is after adjusting ₹31,417,862 already deposited by the company under protest.

Company's Stance and Next Steps

Panacea Biotec has stated that based on their assessment, the aforesaid demand is not maintainable. The company is taking all necessary steps to address this issue, including evaluating the option of filing an appeal against the demand.

Impact on Operations

Despite the substantial amount involved, Panacea Biotec does not anticipate any significant impact on its financial, operational, or other activities. This suggests that the company is confident in its financial stability and its ability to manage this tax liability.

Conclusion

As Panacea Biotec navigates this new GST demand, investors and stakeholders will be closely watching how the company handles this financial obligation and its potential implications on the company's future performance. The company's proactive disclosure and stated intention to challenge the demand demonstrate its commitment to transparency and protecting its financial interests.